Corporate Overview

img

Alzheimer's Disease Facts and Figures

Alzamend Neuro™, Inc., (“Alzamend™)” is a Delaware corporation with its corporate headquarters in Tampa, Florida with nexus in California. The mission of Alzamend Neuro™ is to help the Alzheimer’s community by supporting the full product development life cycle of treatment and cures for Alzheimer’s Disease (“AD”) driven by the belief that strong support of research is the foundation for true innovation. The Company is providing hope through the commercialization of existing patented intellectual properties and know-how while simultaneously funding future treatments for other neurodegenerative diseases and psychiatric disorders, through advanced research and development.

Alzamend Neuro™ is currently working to transition two therapeutics targeting Alzheimer’s disease (“AD”) and psychiatric disorders from the research and preclinical stage into clinical stage and towards full commercialization. Our lead candidate, AL001, is a patented ionic co-crystal technology delivering a therapeutic combination of lithium, proline and salicylate, for the treatment of Alzheimer’s and other neurodegenerative diseases and psychiatric disorders. Our second candidate, AL002, is a patented method using a mutant peptide sensitized cell as a cell-based therapeutic vaccine which seeks to restore the ability of the patient’s immunological system to combat Alzheimer’s. The proposed mechanism of action of AL002 is through the pulsed-Dendritic Cell (“DC”) activation of T-cells that stimulates the immune system, resulting in the clearance of brain amyloid. There are no profound treatments today for Alzheimer’s disease and psychiatric disorders. With AL001 and AL002, the Company believes that we can change that.

 

“Together We Can “Make Alzheimer’s Just a Memory!”™

Our Leadership

Stephan Jackman

Chief Executive Officer and Director 20+ years multi-industry experience, specialized in Biotech and Pharmaceutical LEARN MORE

Kenneth S. Cragun

Senior Vice President of Finance 30+ Years SEC reporting, CFO of publicly-traded company on Nasdaq, multi-industry experience, including Biotech and Healthcare LEARN MORE

Henry C.W. Nisser

Executive Vice President, General Counsel and Director 20+ years experience, U.S. securities compliance, M&A, equity/debt financings and corporate governance LEARN MORE

David J. Katzoff

Chief Operating Officer 30+ Years multi-industry experience, including Healthcare and Technology LEARN MORE

Lien T. Escalona

Chief Financial Officer 25+ Years multi-industry experience with an emphasis on accounting and finance, system implementation and SEC reporting LEARN MORE

Our Board of Directors

Milton C Ault, III

Founder/Chairman Emeritus of Alzamend Executive Chairman of Ault Global Holdings 27+ years Financial Industry experience, seasoned Wall Street CEO & activist investor LEARN MORE

Stephan Jackman

Chief Executive Officer and Director 20+ years multi-industry experience, specialized in Biotech and Pharmaceutical LEARN MORE

William B. Horne

Chairman of Alzamend, Chief Executive Officer of Ault Global Holdings 25+ years Financial Industry experience, prior “Big 4” auditor and healthcare executive LEARN MORE

Henry C.W. Nisser

Executive Vice President, General Counsel and Director 20+ years experience, U.S. securities compliance, M&A, equity/debt financings and corporate governance LEARN MORE

Jeffrey Oram

Principal at Godby Realtors 25+ years multi-industry experience, Investments, Real Estate and Technology LEARN MORE

Mark Gustafson C.P.A.

Chief Financial Officer of PharmaKure Limited 30+ years multi-industry experience as an active CPA, specialized in Biotech, Energy and Technology LEARN MORE

Lynne Fahey McGrath, M.P.H., Ph.D.

Regulatory Affairs and Product Development Consultant 30+ years experience, Biotech and Pharmaceuticals MPH/PHD, Public Health from UMDNJ – Robert Wood Johnson Medical School LEARN MORE

Andrew H. Woo M.D., Ph.D.

Practicing physician at Santa Monica Neurological Consultants, Assistant Clinical Professor of Neurology at the David Geffen School of Medicine at UCLA and Cedars-Sinai Medical Center 20+ years experience in Psychiatry and Neurology LEARN MORE

Our Scientific Advisory Board

Eric M. McDade, DO

Associate Director of the DIAN Trials Unit and Clinical Trials Leadership at Washington University School of Medicine Associate Professor of Neurology, Washington University School of Medicine 157+ Peer-Reviewed Journal Publications LEARN MORE

Thomas M. Wisniewski, MD

Director of NYU Langone’s Pearl I. Barlow Center for Memory Evaluation and Treatment 300+ Peer-Reviewed Medical Journal Publications (19 U.S. Patents Issued) Leads a Research Laboratory Continuously Funded by the National Institutes of Health for 20+ Years LEARN MORE